Who Paid My Doc
Ocrelizumab RMS High Dose Study
Research payments
$12,915,979
Through program year 2025, $12,915,979 in research payments was reported against Ocrelizumab RMS High Dose Study, across 664 payments.
- Paid by (largest first)
- Genentech, Inc.; F. Hoffmann-La Roche AG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,823,354 | 153 |
| 2024 | Research | $3,495,843 | 144 |
| 2023 | Research | $1,665,467 | 106 |
| 2022 | Research | $2,803,850 | 157 |
| 2021 | Research | $3,127,465 | 104 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Derrick Robertson Tampa, FL Named on 29 payments
- Sibyl Wray Knoxville, TN Named on 27 payments
- Christopher Wilson Avon, IN Named on 16 payments
- Lucas Kipp Palo Alto, CA Named on 13 payments
- Joshua Katz Wellesley, MA Named on 13 payments
- Robert Naismith Saint Louis, MO Named on 13 payments
- Ariel Antezana Brooklyn, NY Named on 12 payments
- Emily Riser Birmingham, AL Named on 12 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.